In the long human effort to prevent heart disease before it strikes, a major clinical trial has arrived at a humbling equivalence: whether physicians used advanced imaging of arterial calcium or time-tested risk calculations to decide who should take cholesterol-lowering statins, the rates of heart attacks and strokes were the same. The CorCal Outcomes trial, presented at the 2026 European Society of Cardiology Congress, enrolled nearly 5,800 patients over four years and found that the path to the destination mattered less than whether patients actually walked it — those shown physical evidenc
CAC Scoring Shows No Cardiovascular Benefit Over Traditional Risk Assessment for Statins
Seeing plaque on a scan moves patients to take prevention seriously
Mark
So the study found no difference in heart attacks and strokes between the two groups. That sounds like CAC imaging didn't help. Why would anyone use it?
Mimi
Not quite. The study found identical event rates, which is actually interesting because CAC patients got far fewer statin recommendations—three times fewer. Yet they did just as well. That suggests CAC might be more selective without sacrificing outcomes.
Luke
But we need to be careful here. The study didn't prove CAC was noninferior. It failed to meet that statistical threshold. The p-value was 0.045, which is right at the edge. With lower-than-expected events, the study was underpowered.
Mimi
Right. The researchers are saying this is hypothesis-generating, not conclusive. But the adherence finding is real and striking: 62 percent of CAC patients took their statins versus 23 percent in the traditional group.
Mark
Why would seeing a calcium score on a scan make people more likely to take a pill?
Mimi
Seeing your own plaque on an image is concrete. A risk score is abstract. Patients understand "you have calcium in your arteries" in a way they might not understand "your 10-year risk is 12 percent."
Luke
That's plausible, but it's not measured in the trial. We're inferring motivation from adherence rates. We don't actually know why the CAC group stuck with their medication better.
Mark
So what happens next?
Mimi
The researchers say this trial should inform the design of a larger study. They need more events, more power, to actually test whether CAC-guided selection is noninferior or superior.
Luke
And in the meantime, guidelines already say CAC can be considered as a risk modifier for borderline cases. So some doctors are probably using it already, even though this trial didn't prove it changes outcomes.
Il Polso
- A four-year trial of 5,772 patients found that two competing methods for selecting statin candidates — one using CT imaging, one using traditional risk scores — produced identical cardiovascular event rates of 2.7%, leaving the field without a clear winner.
- The CAC-guided approach dramatically reduced how often statins were recommended, raising the uncomfortable possibility that better targeting may mean leaving some at-risk patients untreated.
- A striking adherence gap emerged: patients who saw their own arterial calcium scores took their statins at nearly three times the rate of those given abstract risk numbers, suggesting that visible evidence changes behavior in ways that statistics cannot.
- The trial failed to meet its statistical threshold for noninferiority, largely because heart events occurred far less often than researchers anticipated, leaving the core question unanswered rather than resolved.
- Investigators are now calling for a larger, better-powered trial, while European cholesterol guidelines already recommend CAC scoring as a risk modifier — a recommendation now sitting in uncertain territory.
In the long human effort to prevent heart disease before it strikes, a major clinical trial has arrived at a humbling equivalence: whether physicians used advanced imaging of arterial calcium or time-tested risk calculations to decide who should take cholesterol-lowering statins, the rates of heart attacks and strokes were the same. The CorCal Outcomes trial, presented at the 2026 European Society of Cardiology Congress, enrolled nearly 5,800 patients over four years and found that the path to the destination mattered less than whether patients actually walked it — those shown physical evidence of plaque in their arteries were nearly three times more likely to take their prescribed medication. Medicine is reminded, once again, that knowledge alone does not heal; belief in that knowledge does.
A clinical trial presented at the 2026 European Society of Cardiology Congress set out to answer a pressing question in preventive medicine: does imaging the calcium deposits inside coronary arteries lead to better statin prescribing decisions than the traditional method of weighing age, cholesterol, and blood pressure? After following nearly 5,800 patients from Utah's Intermountain Health Care system for more than four years, the answer was, in effect, neither approach won.
The CorCal Outcomes trial randomly assigned patients — average age 64, no prior heart disease or statin use — to receive statin recommendations based either on standard pooled cohort risk equations or on coronary artery calcium scores derived from CT scans. Both patients and physicians retained final say over treatment. When researchers tallied major cardiovascular events including heart attacks, strokes, and death, both groups landed at exactly 2.7%, a result so symmetrical it offered no statistical basis for declaring one method superior.
Beneath that equivalence, however, lay a meaningful behavioral divide. Physicians recommended statins more than three times as often to patients in the traditional risk group — yet those patients took their medication at a rate of just 23%. Among CAC-guided patients, where recommendations were rarer but grounded in visible imaging evidence, adherence reached 62%. Seeing plaque on a scan, it appears, motivates action in a way that probability scores do not.
Principal investigator Dr. Joseph B. Muhlestein acknowledged that the trial's lower-than-expected event rates undermined its statistical power, leaving the central question open rather than closed. He framed the findings as hypothesis-generating — useful for designing a larger trial capable of detecting real differences if they exist. European guidelines already incorporate CAC scoring as a tool for borderline-risk patients, though whether this trial's neutral outcome will prompt a reassessment remains unresolved.
A large clinical trial presented at the European Society of Cardiology Congress in 2026 found that two fundamentally different approaches to deciding who should take statins—one based on imaging that shows calcium buildup in coronary arteries, the other based on traditional risk factors like age, cholesterol, and blood pressure—produced identical results when it came to preventing heart attacks and strokes.
The CorCal Outcomes trial enrolled 5,772 patients without known heart disease, diabetes, or prior statin use from the Intermountain Health Care system in Utah. Participants had an average age of 64, and just over half were women. Researchers randomly assigned them to one of two groups: one received statin recommendations based on the pooled cohort equations, a standard algorithm that weighs traditional cardiovascular risk factors, and the other received recommendations based on coronary artery calcium (CAC) scoring, which uses a CT scan to measure the amount of plaque already present in the coronary arteries. Both patients and their physicians received protocol-directed guidance, but made their own final treatment decisions.
After following these patients for an average of 4.2 years, the researchers tracked major cardiovascular events—death from any cause, heart attack, stroke, or the need for arterial procedures. The results were striking in their equivalence: 2.7 percent of patients in each group experienced one of these events. The study did not meet its statistical threshold for demonstrating that CAC-based selection was noninferior to the traditional approach.
What differed sharply between the groups was how often doctors recommended statins and how often patients actually took them. Physicians recommended statins more than three times as frequently to patients in the traditional risk factor group compared to those in the CAC group. Yet when CAC scores prompted a statin recommendation, patients were far more likely to fill and take the medication—62 percent adhered to therapy versus just 23 percent in the traditional risk group. This suggests that seeing physical evidence of plaque on a scan may motivate patients to take prevention seriously in a way that abstract risk numbers do not.
Dr. Joseph B. Muhlestein, the principal investigator from Intermountain Medical Center, noted a persistent problem in cardiovascular medicine: many younger patients experience a heart attack as their first sign of disease, yet current risk assessment tools would never have flagged them as candidates for preventive statin therapy. He acknowledged that the trial's lower-than-expected event rates limited its statistical power to detect meaningful differences between the two approaches. The study did, however, generate what researchers call hypothesis-generating insights—clues about how statin decisions might be made more efficiently and how to improve medication adherence.
Muhlestein concluded that the findings could inform the design of a larger, better-powered trial to clarify whether CAC scoring offers genuine advantages over traditional risk assessment. The 2025 update to European guidelines on cholesterol management already recommends considering CAC scores as a risk modifier for patients at moderate risk or those sitting near the threshold for treatment decisions. Whether that recommendation will shift in light of this trial's neutral findings remains an open question.
Citazioni salienti
For a high percentage of individuals, especially younger individuals with a first heart attack, current risk assessment tools would not have identified them as being at sufficiently high risk to warrant statin therapy.— Dr. Joseph B. Muhlestein, Principal Investigator, CorCal Outcomes trial
The study did provide important hypothesis-generating insights into the efficiency of statin initiation and adherence when decisions are based on CAC scoring.— Dr. Joseph B. Muhlestein
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗
Health & Medicine